This document discusses a clinical trial being conducted by Ocata Therapeutics to evaluate the safety and efficacy of retinal pigment epithelium (RPE) cell transplantation for dry age-related macular degeneration (AMD). Previous phase 1 trials showed anatomical engraftment and functional improvement in vision. The current phase 2 trial will evaluate three regimens of short-term immunosuppression to prevent rejection of the transplanted cells. Safety will be the primary outcome measured with the goal of establishing a protocol to maintain graft survival without long-term immunosuppression.